

Curriculum Vitae

Prof Stephan Windecker, MD, FESC

Office Address: Department of Cardiology
University Cardiovascular Center
Bern University Hospital, Inselspital
3010 Bern, Switzerland



PRESENT APPOINTMENT

2015- Chairman and Professor
Department of Cardiology, University Cardiovascular Center
Bern University Hospital, Inselspital, Bern, Switzerland

PREVIOUS POSITIONS

2009-2015 Physician-in-Chief
Department of Cardiology, University Cardiovascular Center
Bern University Hospital, Inselspital, Bern, Switzerland

2002-2015 Director, Invasive Cardiology, Department of Cardiology, Bern University
Hospital, Inselspital, Bern Switzerland

ACADEMIC DEGREE AND INTRA- AND EXTRAMURAL RESPONSIBILITIES

2010 - Professor of Cardiology, University of Bern, Switzerland

2020 - Vice-Dean, Faculty of Medicine, University of Bern, Switzerland

2020 - Member, Clinical Study Group, Deutsches Zentrum für Herz-Kreislauf-
Forschung, Germany

2023 - Expert Advisory Panel, Global Cardiovascular Research Funder Forum-GCRFF

EUROPEAN SOCIETY OF CARDIOLOGY

2022- Vice-President of the European Society of Cardiology

2020-2022 Chair, ESC Congress Program Committee

2016-2020 Chair, ESC Clinical Practice Guideline Committee

2016- Board Member of the European Society of Cardiology

2014-2016 President, EAPCI

ESC – TASK FORCE ON MEDICAL DEVICES

- 2022 ESC Cardiovascular Roundtable on “Device Innovation in Cardiovascular Medicine”, Paris, France
- 2013-2017 Chairperson - Task Force
Revision of the EU medical device advisory document on the evaluation of coronary stents (MEDDEV 2.7.1.)
Byrne R, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, Oktay S, Jüni P, Kastrati A, Sianos G, Stefanini G, Wijns W, **Windecker S**.
Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J* 2015;36:2608-20

SWISS SOCIETY OF CARDIOLOGY

- 2002 - Member of the Swiss Society of Cardiology
- 2008-2010 President of the Working Group Interventional Cardiology and Acute Coronary Syndromes
- 2012-2016 Board Member, Swiss Society of Cardiology

RESEARCH INTERESTS

Clinical trials with focus on the evaluation of intracoronary devices and drugs for the treatment of coronary artery disease, antithrombotic therapy for patients requiring cardiac device implantation, and research related to minimal-invasive heart valve treatment including transcatheter aortic, mitral and tricuspid valve interventions. He has authored more than 900 original scientific articles in peer reviewed journals and more than 100 review articles.

SELECTED PUBLICATIONS

1. **Windecker S**, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. *N Engl J Med* 2005;353:653-62
2. **Windecker S**, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer For Coronary Revascularisation: A Randomised Controlled Trial. *Lancet* 2008;372:1163-73
3. Serruys PW, Silber S, Garg S, van Geuns J, Richardt G, Buszman P, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen, **Windecker S**. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010;363:136-46
4. Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuillomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli F, Wenaweser P, Jüni P, **Windecker S**. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularization (BIOSCIENCE): a randomized, single-blind, non-inferiority trial. *Lancet* 2014;384:2111-22

5. Siontis G, Stefanini G, Mavridis D, Siontis K, Alfonso F, Pérez-Vizcayno M, Byrne R, Kastrati A, Meier B, Salanti G, Jüni P, **Windecker S**. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 2015;386:655-64
6. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, **Windecker S**; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018;392:940-949
7. Lanz J, Kim WK, Walther T, Burgdorf C, Möllmann H, Linke A, Redwood S, Thilo C, Hilker M, Joner M, Thiele H, Conzelmann L, Conradi L, Kerber S, Schymik G, Prendergast B, Husser O, Stortecky S, Heg D, Jüni P, **Windecker S**, Pilgrim T; SCOPE I investigators. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. *Lancet*. 2019;394:1619-1628.
8. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, **Windecker S**; GALILEO Investigators. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. *N Engl J Med*. 2020; 9;382:120-129.
9. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini AS, Veien KT, Abdel-Wahab M, Kim WK, Balan P, Van Mieghem N, Mathiassen ON, Jeger RV, Arnold M, Mehran R, Guimarães AHC, Nørgaard BL, Kofoed KF, Blanke P, **Windecker S**, Søndergaard L; GALILEO-4D Investigators. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. *N Engl J Med*. 2020; 382:130-139.
10. **Windecker S**, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Abdul Ghapar AKB, Selvaraj K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbiochi F, Pasupati S, Kim HS, Aminian A, Tie C, Włodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW; ONYX ONE Investigators. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*, 2020;382:1208-1218.
11. Siontis GM, Coles B, Häner J, McGovern L, Bartkowiak J, Coughlan JJ, Spirito A, Galea R, Haeblerlin A, Praz F, Tomii D, Melvin T, Frenk A, Byrne RA, Fraser AG, **Windecker S**. CORE-MD investigators. Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium. *Eur Heart J* 2023 doi: 10.1093/eurheartj/ehad567
12. Iglesias JF, Roffi M, Losdat S, Muller O, Degrauwe S, Kurz DJ, Haegeli L, Weilenmann D, Kaiser C, Tapponnier M, Cook S, Cuculi F, Heg D, **Windecker S**, Pilgrim T. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. *Lancet*. 2023 doi: 10.1016